Loading...
•
Sep 30, 2024
Theravance Q3 2024 Earnings Report
Theravance Biopharma reported strong YUPELRI demand, driving quarterly net sales to an all-time high, and reaffirmed CYPRESS development timelines.
Key Takeaways
Theravance Biopharma reported financial and operational results for the third quarter of 2024, highlighting strong YUPELRI demand and progress on the CYPRESS study. The company also announced the formation of a Strategic Review Committee to assess alternatives to unlock shareholder value.
Achieved a strong quarter for YUPELRI demand through collaboration with Viatris.
Quarterly net sales reached an all-time high.
Reaffirmed development timelines for CYPRESS.
Formed a Strategic Review Committee to assess alternatives to unlock shareholder value.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Theravance Biopharma has not set a timetable for completion of the strategic review process, and it does not intend to disclose further developments unless and until it determines that such disclosure is appropriate or necessary.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...